by TractManager | Jul 31, 2019 | News
Today, the Food and Drug Administration (FDA) approved Nubeqa (darolutamide; Bayer and Orion Corporation), an androgen receptor inhibitor for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). FDA approval was based on the...
by TractManager | Jul 29, 2019 | News
The Food and Drug Administration (FDA) has issued a safety communication regarding risk of blood clots and of death with a 10 mg twice daily dose of Xeljanz/Xeljanz XR (tofacitinib; Pfizer Inc.). Xeljanz is a janus kinase inhibitor that was first approved in 2012 to...
by TractManager | Jul 26, 2019 | News
CDC Update: Recommendations for Measles in Healthcare SettingsThe Centers for Disease Control and Prevention (CDC) have released interim infection prevention and control recommendations for measles in healthcare settings. Since 2000, when measles was declared...
by TractManager | Jul 25, 2019 | News
These Food and Drug Administration (FDA) developments came in this week:First Nasal Glucagon Approved for Severe HypoglycemiaThe FDA has granted approval to Baqsimi (glucagon; Eli Lilly and Company), an anti-hypoglycemic agent for the treatment of severe hypoglycemia...
by TractManager | Jul 24, 2019 | Health Technology Assessment
Health Problem: Chronic pain, or pain persisting > 6 months, is a multifaceted condition with an estimated prevalence of 2% to 40% in adults in the United States. There are numerous etiologies of chronic noncancer pain. Treatment of chronic pain depends on individual...
Recent Comments